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Executive summary
This document describes how clinical services for the management of substance 
misusers in prison should develop during the next two years as increasing resources 
permit. The aim is to address the current challenges facing the care and treatment of 
substance misusers in prisons. These include:
•	 the vulnerability of drug-using prisoners to suicide and self-harm in prison, 
and to death upon release from custody due to accidental opiate overdose;
•	 prison	regime	management	problems	related	to	illicit	drug	use	in	prisons;
•	 the	impetus	to	provide	clinical	services	that	correspond	to	national	(NTA	
2003) and international good practice;
•	 the	need	to	provide	clinical	interventions	that	harmonise	with	practice	in	
community	and	other	criminal	justice	settings	(NOMS	2005);
•	 the	need	to	integrate	further	healthcare	and	Counselling,	Assessment,	
Referral,	Advice	and	Throughcare	(CARAT)	services	in	prisons,	to	create	
multi-disciplinary drug teams.
To these ends, this document has been drafted in consultation with key government 
departments, professional organisations, commissioning organisations and service 
providers. These include:
•	 HM	Prison	Service;
•	 Department	of	Health;
•	 Home	Office;
•	 National	Treatment	Agency;
•	 National	Addiction	Centre;
•	 National	Offender	Management	Service	Drug	Strategy	Unit;
•	 Prison	Officers’	Association;
•	 Royal	College	of	Psychiatrists;
•	 Royal	College	of	General	Practitioners.
The	document	also	takes	account	of	work	being	progressed	through	the	Drug	
Interventions	Programme	(formerly	known	as	the	Criminal	Justice	Interventions	
Programme	–	CJIP).
In recent years, there has been substantial progress in the provision of non-clinical 
drug	services	across	the	prison	estate.	Clinical	services	have	been	slow	to	develop	
by	comparison.	Detoxification,	of	a	pre-set	duration,	remains	the	solitary	prescribing	
response to drug dependence in the majority of local prisons. 
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While	detoxification	may	remain	the	preferred	method	of	clinical	management	for	
some drug-dependent prisoners, it is now apparent that a range of clinical treatment 
options are required to manage the varied and complex needs of this patient group. 
The principal elements of this model are as follows:
•	 Prescribed	management	of	withdrawal	by	a	doctor	in	reception	in	a	local	
prison, to lower risk of suicide, informed by the reception health screening 
and assessment.
•	 Stabilisation	on	a	licensed	opiate	substitute	medication	for	a	minimum	
of	five	days	prior	to	progression	to	one	of	the	following	three	treatment	
options:
	 1.	 standard	opiate	detoxification	(minimum	duration	of	14	days);
	 2.	 extended	opiate	detoxification	(21	+	days);
	 3.	 	opiate	substitute	maintenance	(up	to	13	weeks	or	beyond,	dependent	
on individual clinical need).
•	 Safe	and	effective	alcohol	detoxification	in	line	with	the	Prison	Alcohol	
Strategy	(2004).
•	 Effective,	evidence-based	management	of	benzodiazepine	withdrawal	
(BNF	2005,	DH	1999).
•	 Clinical	monitoring	of	stimulant	withdrawal.
•	 Good-quality	joint	working	and	case	management	between	clinical	teams,	
CARAT	services	and	Criminal	Justice	Integrated	Teams	(CJITs).
•	 Progression,	through	CARAT	case	management,	to	other	Tier	3	and	4	
services in prisons, such as rehabilitation programmes and therapeutic 
communities.
•	 Joint	management	and	care	planning	by	primary	healthcare	teams,	
mental health in-reach services and substance misuse teams of individuals 
with	co-existing	mental	health	and	substance	misuse	problems	(dual	
diagnosis),	with	a	view	to	a	harm-minimisation	approach	(Royal	College	
of	Psychiatrists,	2003).
•	 Ongoing	reviews	of	all	extended	prescribing	regimens,	informed	by	random	
clinical drug tests.
•	 Provision	of	a	minimum	28-day	open	intervention	of	psychosocial	support	
for all prisoners with problematic drug use.
In a local prison, patients should initially be accommodated on a unit that offers access 
to unrestricted 24-hour observation, utilising open healthcare hatches where they have 
been installed. When new-builds or refurbishments are undertaken, these facilities 
should be created. 
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This guidance is intended to serve as a document upon which future developments in 
clinical services in prisons may be commissioned. It is formulated as a treatment model, 
to	cover	a	period	from	reception	into	custody,	up	to	and	beyond	28	days	thereafter.	
It seeks to set out the key components of this type of care, which are reception 
screening, assessment, clinical management and psychosocial interventions.
All	prescribed	regimens	should	be	supported	by	evidence,	conform	to	PSO	3550	
(HM	Prison	Service	2000)	and	DH	(1999)	guidelines	and	adhere	with	the	principles	
of clinical governance.
The model will be supported by an ongoing training programme to ensure that staff 
develop the skills and knowledge required for the competent delivery of the approach 
outlined in this guidance. There should be provision of access to training and support 
for all clinicians working with substance misusers in prisons. 
This guidance is intended for all healthcare professionals working with substance 
misuse in prisons. It is strongly advocated that, wherever possible, prisons and primary 
care teams should seek the involvement of a substance misuse specialist doctor in the 
planning, delivery and support of clinical services.
To inform commissioning and to optimise continuity of care, this guidance should also 
be	made	available	to	primary	care	trusts,	Drug	and	Alcohol	Action	Team	partnership	
commissioners,	community	drug	and	alcohol	treatment	providers,	Drug	Interventions	
Programme	project	managers	and	CJITs.	
This document shall be reviewed within a year in the light of any new research within 
the prison system, the improved training of clinicians working in prisons and the results 
of	the	National	Institute	for	Health	and	Clinical	Excellence	guidance	and	technology	
appraisals of buprenorphine, methadone and naltrexone.   
This	model	applies	only	to	prisoners	aged	18	or	over.	Guidance	on	the	clinical	
management of substance misuse problems for younger people in secure settings 
will be published later this year.
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1 Introduction
1.1	 There	is	an	increasing	awareness	within	the	Prison	Service	of	a	correlation	
between drug withdrawal and self-destructive behaviours. One of the principal 
recommendations	from	the	Prison	Service	internal	review	of	prevention	of	
suicide and self-harm in prisons is that:
‘The	Prison	Service	should	pay	special	attention	to	the	safe	management	
of prisoners in the early stages of custody in a prison, with a focus on 
excellence	of	care	for	all	prisoners	in	reception,	first	night,	induction	
and	detoxification	units.’
(HM	Prison	Service	2001a)
1.2 A broader range of clinical responses to drug dependence, such as extended 
opiate	detoxification	and	maintenance	programmes,	could	serve	to	reduce	
incidents of suicide and self-harm among those most at risk, including 
individuals with co-existent drug and mental health problems. Other regime 
management	benefits,	such	as	reduced	drug	smuggling	via	reception	and	fewer	
incidents of violent aggression, have been noted in prisons where a broader 
range of clinical services has been developed.
1.3	 Drug	users	are	at	a	greatly	increased	risk	of	death	during	the	first	week	
of	release	from	prison	(40	times	greater	than	the	average	mortality	rate,	
see	Home	Office	Online	Report	Series	(HOORS)	2003).	The	predominant	
cause of these deaths is accidental drug overdose. Loss of tolerance to the 
toxic	effects	of	opiates	following	detoxification	would	appear	to	be	a	very	
common precipitating factor.
1.4 The range of clinical responses to drug dependence recommended in the 
HOORS	(2003)	study	includes	methadone	maintenance.	In	its	review	of	drug	
policy	and	treatment,	the	Home	Affairs	Select	Committee	(2002)	recommended	
that methadone maintenance should be available across the prison estate. It 
is acknowledged that there has been considerable unease around this practice 
within	the	Prison	Service,	but	through	careful	evaluation	and	study,	it	has	
become apparent that this intervention within a prison setting can lead to 
important	harm	reduction	benefits	(Dolan	2003).	
1.5 A more organised and systematic approach to clinical management across 
the	estate	is	desirable,	taking	into	account	the	patient’s	own	view	on	the	
management of their substance-misuse problems.
1.6	 Individual	clinicians	and	establishments	as	a	whole	will	benefit	from	the	
enhanced protection of a systematic approach to the management of drug 
dependence. This does not of course preclude alternative treatment by an 
addiction specialist where clinically appropriate. This document describes how 
clinical services for the management of substance misusers should develop 
during the next two years as resources permit. This model, which covers a 
period	from	reception	in	to	custody,	up	to	and	beyond	28	days	thereafter,	
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seeks to set out the key components for such an approach, which are reception 
screening, assessment, clinical management and psychosocial interventions. 
1.7	 Continuity	of	care	is	vital	to	the	treatment	and	support	given	to	problematic	
drug-misusing offenders as they move between different criminal justice and 
treatment agencies. Improvement of continuity of care for the individual is 
reliant upon seamless case management through the effective provision and 
communication of the right information at the right time to the right people, 
throughout	the	treatment	‘journey’	of	the	patient.	The	Drug	Interventions	
Record	(DIR)	establishes	a	common	tool	for	use	by	CJITs	in	the	community	
and	drug	treatment	services	in	prison.	The	DIR	features	a	minimum	set	of	
data for monitoring on one side, with additional free text space for continuity 
of care information to enable the worker to describe individual circumstances 
in	more	detail.	The	DIR	facilitates	continuity	of	care	and	minimises	duplication	
of assessments, particularly when individuals are moving between custody 
and community but also when information is passed between case managers 
and/or	treatment	providers	(with	consent).
1.8		 CARAT	teams	are	the	case	managers	for	all	drug	treatment	interventions	in	
prisons and will liaise with prison resettlement workers, probation/offender 
managers	(where	appropriate)	and	CJITs	when	preparing	release	plans	in	order	
to	ensure	that	drug-related	needs	are	identified	pre-release	and	appropriately	
addressed	post-release.	Effective	resettlement	of	any	drug	misuser	requires	
the development of a holistic package of support. Aftercare is the package of 
holistic support that needs to be in place when a drug misuser leaves custody. 
It involves access to additional support with a range of issues that may include 
housing,	managing	finance,	rebuilding	family	relationships,	learning	new	skills	
and	employment.	Early	planning	pre-release	will	enable	continuity	of	care	and	
access to wraparound support to be provided at the time when it is needed.
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2 Risk management
Much	of	clinical	substance	misuse	practice	is	directly	concerned	with	the	management	of	risk.	This	
table summarises methods to manage risks, some of which are particular to clinical substance misuse 
work in a prison setting.
Risk area Risk Recommended management
Self-inflicted	
deaths and drug 
and alcohol 
withdrawal
Heightened	risk	
of suicidal and 
self-injurious 
behaviour among 
opiate-dependent 
prisoners in the 
first	24	hours	of	
custody in prison
Opiate-dependent 
prisoners remain 
at a raised risk of 
suicide and self-
injury throughout 
the	first	28	days	
and, in particular, 
during	the	first	7	
days of custody
Provision	of	prescribing	for	opiate	withdrawal	by	a	doctor	
in reception of a local prison, on the day/evening of 
admission
Opiate withdrawal to be managed by opioid stabilisation 
and	subsequent	planned	care	(section	5.4)
Joint	working	between	clinical	teams	and	residential	staff,	
to include:
information-sharing	protocols	(see	the	SECURE	prisons	•	
mental	health	CD-ROM)	
information and training for residential staff on working •	
on a withdrawal management unit
information	and	training	of	clinical	staff	on	the	Prison	•	
Service’s	multi-disciplinary	risk	management	process	
(ACCT	Plan	or	F2052SH)	for	patients	they	identify	
as at particular risk of suicide or self-harm 
Fatal	overdose	
on leaving prison
Opiate users 
particularly 
vulnerable to 
this risk due 
to diminished 
tolerance
Substitute	opioid	management	of	dependence	
(sections	5.4	and	7)
Effective	continuity	of	treatment	(sections	8	and	11)
Overdose prevention information for patients 
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Risk area Risk Recommended management
Level of opiate 
dependence is 
uncertain
Non-dependent	
individuals may be 
at risk of opioid 
poisoning
Clinical	drug	testing	to	include	morphine,	methadone	
and buprenorphine
Use	of	opioid	withdrawal	assessment	scale	(eg	short	
opiate	withdrawal	scale,	Gossop	1990)	and	intoxication	
monitoring
Ensure	patient	is	fully	alert,	responding	appropriately	and	
that there are NO signs of drowsiness/sedation; withhold 
medication in the event of any concern
Gradual	dose	induction,	with	doses	divided	(section	5.4)
A minimum of twice-daily monitoring of withdrawal and 
intoxication during stabilisation
Where benzodiazepine dependence is also diagnosed, 
diazepam should be prescribed at the lowest dose that will 
prevent	withdrawal	symptoms.	Doses	should	be	divided	for	
at	least	the	first	seven	days	of	treatment.
Staff	training	in	the	administration	of	naloxone	(section	6)
Reduced opiate 
dependence in 
a newly received 
prisoner
Tolerance to 
opiates may 
have diminished 
following a break 
in consumption 
during police 
custody
Clinical	drug	testing	to	include	morphine,	methadone	and	
buprenorphine
Use	of	opioid	withdrawal	assessment	scale	(eg	short	
opiate	withdrawal	scale,	Gossop	1990)	and	intoxication	
monitoring
Ensure	patient	is	fully	alert,	responding	appropriately	and	
that there are NO signs of drowsiness/sedation; withhold 
medication in the event of any concern
Gradual	dose	induction,	with	doses	divided	(section	5.4)
A minimum of twice-daily monitoring of withdrawal and 
intoxication during stabilisation
Where benzodiazepine dependence is also diagnosed, 
diazepam should be prescribed at the lowest dose that will 
prevent	withdrawal	symptoms.	Doses	should	be	divided	for	
at	least	the	first	seven	days	of	treatment
Staff	training	in	the	administration	of	naloxone	(section	6)
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Risk area Risk Recommended management
Increased risk on 
second and third 
day of opioid 
stabilisation
Cumulative	toxicity	
due	to	filling	of	
tissue	‘reservoirs’	
Clinical	drug	testing	to	include	morphine,	methadone	and	
buprenorphine
Use	of	opioid	withdrawal	assessment	scale	(eg	short	
opiate	withdrawal	scale,	Gossop	1990)	and	intoxication	
monitoring
Withhold medication in the event of any concern
Gradual	dose	induction,	with	doses	divided	(section	5.4)
A minimum of twice-daily monitoring of withdrawal and 
intoxication during stabilisation
Where benzodiazepine dependence is also diagnosed, 
diazepam should be prescribed at the lowest dose that will 
prevent	withdrawal	symptoms.	Doses	should	be	divided	for	
at	least	the	first	seven	days	of	treatment
Staff	training	in	the	administration	of	naloxone	(section	6)
Varied individual 
responses to 
substitute opioid 
medication
Response may be 
affected by:
impaired •	
liver function 
–	history	of	
injecting drug 
use, heavy 
alcohol use 
or hepatitis
individual •	
variation in 
enzyme activity
Carry	out	liver	function	test	where	liver	compromise	is	
suspected
Clinical	drug	testing	to	include	morphine,	methadone	and	
buprenorphine
Use	of	opioid	withdrawal	assessment	scale	(eg	short	
opiate	withdrawal	scale,	Gossop	1990)	and	intoxication	
monitoring
Ensure	patient	is	fully	alert,	responding	appropriately	and	
that there are NO signs of drowsiness/sedation; withhold 
all central nervous system depressant medication in the 
event of any concern, pending medical reassessment
Gradual	dose	induction,	with	doses	divided	(section	5.4)
A minimum of twice-daily monitoring of withdrawal and 
intoxication during stabilisation
Where benzodiazepine dependence is also diagnosed, 
diazepam should be prescribed at the lowest dose that will 
prevent	withdrawal	symptoms.	Doses	should	be	divided	for	
at	least	the	first	seven	days	of	treatment
Staff	training	in	the	administration	of	naloxone	(section	6)
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Risk area Risk Recommended management
Drug	
cautions and 
contraindications
Opioid prescribing is contraindicated for patients with 
either acute respiratory depression or paralytic ileus
Caution	required	in	cases	of	hepatic	impairment,	renal	
impairment and recent head injury
Extend	frequency	and	duration	of	monitoring	as	necessary
Consult	British	National	Formulary	(BNF)
In complex cases, seek specialist advice
Drug	
interactions
Effects	of	opioid	
medication may 
be enhanced 
or reduced 
by concurrent 
medication 
As drug cautions and contraindications above
Refer	to	drug	interactions	chart,	Annex	14	of	DH	(1999)
See	also	Appendix A of this document
Seek	specialist	advice	when	required
Extend	frequency	and	duration	of	monitoring	as	necessary
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Risk area Risk Recommended management
Diversion	of	
prescribed 
medication	(high	
black market 
value in prison 
relative to the 
community) 
Patients	may	
be subject to 
intimidation
Medication	may	
be diverted to 
naïve individual
Supervise	consumption	of	controlled	drug	and	other	drugs	
subject to misuse within prison
Administer buprenorphine as follows:
The	oral	cavity	(including	the	area	under	the	tongue)	1. 
is examined prior to administration to ensure that 
no	substitute	‘tablet’	or	other	foreign	objects	are	
concealed there
The patient should consume some water 2. 
The	tablet	or	tablets	are	put	under	the	patient’s	tongue	3. 
by a member of staff who remains in the same room as 
the patient throughout the administration process
The patient is observed throughout the dissolving 4. 
phase, with at least one check during this process to 
ensure that the medication remains under the tongue
The	observing	member	of	staff	confirms	that	the	5. 
medication has dissolved completely
The patient should consume a drink of water6. 
 Prison	Health	(2004)
Guidance	on	the	circumstances	under	which	
buprenorphine may be crushed can be found on www.
pjonline.com/editorial/20050402/society/p401crushing.
html
Supervise	consumption	of	methadone	followed	by	the	
administration of at least 200ml of water
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Risk area Risk Recommended management
Observation 
inhibited by 
locked cell doors
Suicidal	behaviour/
serious self-harm 
risk exacerbated 
by unmanaged 
withdrawal
Overdose	difficult	
to identify 
within these 
circumstances
Where	possible,	fit	cell	doors	with	healthcare	hatches;	
these hatches should ordinarily be kept open at all times 
 
 
Involve	patients	in	purposeful	activity	(including	
psychosocial interventions) with adequate time out of cell 
Vulnerability of 
stimulant users
Acute intoxication 
may cause cardiac 
or cerebrovascular 
events
Sudden	lowering	
of mood may 
trigger suicidal 
ideation and self-
harm attempts
Clinical	team	should	daily	monitor	stimulant	users	
who test positive for stimulants in reception for the 
first	three	days	of	custody	(incorporating	blood	pressure	
and neuro-observation)
Encourage	users	to	engage	in	psychosocial	interventions
Care	delivered	
by both 
specialist and 
non-specialist 
practitioners
Varying levels 
of competence 
can result in 
inappropriate 
treatment
Protocol	system	for	assessment	and	prescribing,	validated	
by primary care trust/prison partnership clinical governance 
committee
Give	non-specialist	practitioners	access	to	specialist	advice
Ongoing clinical training and supervision programme
Very high 
volume of 
treatments in 
local prisons
Misidentification	
of patients; 
duplication 
of drug 
administration
Consistent	with	good	planning	practice,	include	
photographic	or	biometric	identification	of	patients	in	the	
drug administration process
All opioid drug administration to be observed and 
witnessed, both parties to sign the relevant documentation, 
the patient to sign as well to agree that they have received 
the medication
Healthcare	staff	should	verify	patient	details	when	
arranging continuity of a community prescription 
(section	8)
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Risk area Risk Recommended management
Lay staff on 
residential 
units may 
not recognise 
symptoms of 
withdrawal or 
intoxication
Clinical	team	
may not be made 
aware of patients 
requiring urgent 
clinical attention 
Provide	awareness	and	referral	training	for	residential	staff
Draw	up	protocols	to	facilitate	communication	between	
clinical	and	lay	staff	(SECURE	CD-ROM)
Management	
of drug 
dependence in 
pregnancy
Poorly	managed	
withdrawal may 
result in clinical 
complications
Manage	patient	with	divided	doses	for	as	long	as	necessary
Contact	community	midwife	immediately	(section	14.2)
Impact of 
substance 
withdrawal on 
patients with a 
mental health 
problem
Patients	may	
experience a 
re-emergence or 
exacerbation of 
mental distress 
Pace	prescribed	management	to	minimise	psychological	
duress
Implement shared care planning arrangements between 
healthcare,	mental	health	and	CARAT	teams	(section	13)
Disposal	of	
drugs
Need	for	safe	
disposal of drugs 
NHS	Estates	will	shortly	be	issuing	guidance	on	the	safe	
disposal of healthcare waste, including returned and 
surplus medicines. Interim guidance for pharmacists 
appears	on	the	Royal	Pharmaceutical	Society	of	Great	
Britain website:
www.rpsgb.org.uk/pdfs/hazwastecommphguid.pdf
www.rpsgb.org.uk/pdfs/hazwastehospphguid.pdf
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3 Reception screening process
3.1 A new healthcare screening process has been introduced across all prisons that 
take offenders from court. The purpose of reception screening for substance 
misuse is to enquire about drug and alcohol use, and to screen for evidence 
of	dependence	in	those	who	report	current	or	recent	use.	Secondly,	reception	
screening seeks to determine immediate healthcare needs, including withdrawal, 
for which there should be access to adequate and effective prescribing by a 
doctor for management upon reception into local prison custody. Wherever 
possible, location should be in a unit that offers access to unrestricted observation 
at all times 24 hours a day by healthcare staff trained in substance misuse. This 
observation	is	best	made	through	open	healthcare	hatches	(HM	Prison	Service	
2000).	Healthcare	hatches	are	recommended	for	initial	accommodation	for	
prisoners as they can afford a level of observation that includes visual, oral, 
auditory, olfactory and tactile communication and monitoring. A system based on 
agreed protocols should provide management options at this phase of custody. 
Prisoners	who	are	primarily	or	exclusively	stimulant	users	should	also	be	provided	
accommodation in a unit that offers enhanced observation.
3.2 Reception screening has to be brief and, in a local prison, should be focused 
to ensure that appropriate prescribed clinical management is undertaken by 
a doctor upon reception. In cases of opiate dependence in local prisons, this 
should be the commencement of a period of prescribed stabilisation, with 
an	opiate	agonist.	Commissioners	may	decide	to	meet	this	requirement	by	
contracting a doctor into reception or through an on-call system. Where the 
latter is provided, there must be provision for the doctor to visit the prison, 
assess and prescribe for the patient. There should be enough time and resources 
for the doctor to make an adequate assessment. This option would normally 
be	preferred	for	those	arriving	‘out	of	hours’.
3.3	 There	are	methodological	problems	facing	the	assessing	doctor.	Prison/primary	
care trust partnerships should therefore devise systems to improve this process 
–	for	example,	consistent	clinical	recording,	accurate	drug	screening	tests,	
and nurses and healthcare workers trained in substance misuse to assist in the 
assessment and recording process. It may also be useful to investigate ways of 
improving	communication	between	the	prisoner’s	GP	and	the	assessing	doctor.	
3.4 Knowledge and information should be provided during initial assessment about 
what will occur during the withdrawal process and a reassurance given that the 
service is available to support the individual in an active management regime. 
For	those	patients	progressing	to	detoxification,	knowledge	and	awareness	
of	the	withdrawal	process	significantly	reduces	stress	and	improves	overall	
outcome. Written information should be more generally available and should 
include information on both the choice and length of treatment, consequences 
–	both	physical	and	psychological	–	of	withdrawal,	and	the	potential	benefits	
of	seeking	help	in	coping	with	these	experiences.	Plainly	expressed	warnings	
regarding	the	risks	of	overdose	should	also	be	provided	–	in	pictorial	and	
written form.
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3.5 In the initial stage, drug testing is critical to establishing current opiate or other 
drug use. It is particularly important to establish the presence of morphine or 
other opioid metabolites where a self-report of opioid use has been made. 
Where	they	are	available,	CJIT	assessments	that	include	Class	A	drug	test	
results should be incorporated into the assessment procedure. In circumstances 
where a drug screen does not detect opiates, clear signs of withdrawal must 
be observed before medicated management is considered. A validated opiate 
withdrawal	scale,	such	as	the	short	opiate	withdrawal	scale	(Gossop	1990),	
should be used to determine the presence of withdrawal. Withdrawal from 
benzodiazepines and alcohol may complicate the clinical picture and caution 
is	recommended	in	cases	of	uncertainty.	Subsequently,	clinical	drug	testing	
can be used to monitor further use of non-prescribed drugs. 
3.6	 Staff	should	be	aware	of	the	psychological	effects	of	nicotine	withdrawal,	
which include agitation and impulsiveness.
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4 Assessment 
4.1 The clinical assessment following reception should be undertaken by a 
competent nurse, pharmacist or doctor. It should include a full drug use history, 
including	past	and	current	injecting	(with	inspection	of	injection	sites	and	
abscesses), and details of current community treatment. As continuity of care 
is	central	to	effective	treatment,	healthcare	teams	should	use	the	revised	DIR	as	
the	initial	(ie	‘triage’)	substance-misuse	assessment	document.	This	will	facilitate	
entry	into	the	Integrated	Drug	Treatment	System	for	prisons	and	access	to	
continued	care	through	the	Drug	Interventions	Programme	(National	Treatment	
Agency	2005).	The	healthcare	practitioner	should	complete	the	DIR	up	to	and	
including	the	healthcare	section	and	pass	the	form	to	a	member	of	the	CARAT	
team for its completion. It is essential that there is accurate documentation of 
this assessment entered in the patient medical records. When a prisoner states 
that they are on a community treatment programme, corroborative prescribing 
information	should	be	sought	(see	section	8). It will be necessary to stabilise 
prescribing	(see section 5.4) while the answer from the community clinician 
is	awaited.	Chief	pharmacists	within	primary	care	trusts	can	help	to	locate	
community treatment information.
4.2 Substance	misusers	are	particularly	prone	to	a	number	of	medical	conditions.	
These	include	viral	hepatitis,	HIV,	bacterial	endocarditis,	tuberculosis,	
septicaemia, pneumonia, deep vein thromboses, pulmonary emboli, abscesses, 
thrombophlebitis, dental disease, seizures and other neurological impairments. 
Planned	management,	including	specialist	referral	where	indicated,	is	appropriate	
in such cases. Ongoing clinical monitoring is valuable as the early symptoms of 
drug withdrawal may mask a separate underlying physiological condition.
4.3 Practitioners	should	elicit	information	on	exposure	to	blood-borne	viruses,	sexual	
health risks, and lead on to referral to the appropriate service. The potential 
need for a mental health assessment should form part of the assessment process. 
Where	suicidal	ideation	is	detected,	the	Prison	Service’s	multi-disciplinary	risk	
management	process	(Assessment,	Care	in	Custody	and	Teamwork	or	F2052SH)	
should be instigated. Other clinical interventions may be corroborated by the 
relevant	community	services	(eg	continued	management	of	deep	vein	thrombosis	
and infection management). The opportunity to vaccinate against hepatitis B 
should be maximised.
4.4 The assessment process should also be used to develop a map of the journey 
for	this	particular	treatment	episode.	Part	of	this	function	should	be	to	help	
the individual develop some personal aims and objectives for managing 
their substance misuse. A substantial amount of behavioural change can be 
encouraged by the prison regime and the move into a structured environment 
away	from	high-risk	drug-taking	situations	in	the	community.	Prison	does,	
however, have its own problematic drug culture.
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4.5 The setting in which clinical management occurs varies between establishments. 
In some, it will occur within a healthcare unit, while others may have a 
dedicated	wing.	Those	patients	with	a	mild	dependence	(who	would	be	
managed as outpatients in the community) may be accommodated at a 
residential location provided there are no other medical complications and that 
observations may be carried out by healthcare staff, trained and competent in 
substance	misuse,	in	accordance	with	Prison	Service	Order	3550	(HM	Prison	
Service	2000).	Newly	received	prisoners	need	to	be	made	aware	of	the	setting	
in which stabilisation and further clinical management occurs within that prison. 
This will include obtaining informed consent from the patient for the sharing of 
essential health information with key staff involved with their care, on a need-
to-know basis. This environment should, wherever possible, permit unrestricted 
observation	by	healthcare	staff	24	hours	a	day	for	at	least	the	first	five	days	of	
clinical management, and beyond this period where withdrawal is complex. 
Where they have been installed, healthcare hatches should be kept open to 
facilitate this observation, as described in section 3.1 above. When new builds 
or refurbishments are undertaken, these facilities should be created. 
4.6	 Patients	undergoing	medicated	management	of	their	substance	misuse	who	
leave the prison under temporary licence or under intermittent custody should 
be reassessed when they return.
4.7 All prescribed regimens should be supported by evidence, and conform to 
Prison	Service	Order	3550	and	the	Department	of	Health’s	clinical	guidelines	
(1999),	in	accordance	with	the	principles	of	clinical	governance,	such	as	good	
record	keeping,	clinical	audit	and	significant	event	recording.	It	is	important	to	
reassure new prisoners and make the process of assessment transparent, easily 
understandable and with a goal of reducing the level of arousal and anxiety 
associated with the early stage of imprisonment.
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5 Opioid prescribing: stabilisation 
For	the	purpose	of	this	document,	the	term	‘stabilisation’	means	the	moderating	and	
control of withdrawal symptoms for a given period of time. In prison, this would be for 
a	minimum	of	the	first	five	days	of	custody,	which	is	a	period	of	high	risk	of	suicide	and	
self-harm.	Stabilisation	is	achieved	through	a	process	of	dose	induction	–	the	gradual	
introduction of doses of either methadone or buprenorphine in response to withdrawal 
symptoms.	Dose	induction	is	usually	completed	within	48	to	72	hours,	at	which	point	
the	current	daily	dose	would	be	continued	until	at	least	day	five,	when	a	decision	
would be reached on future clinical management.
5.1 Opiate-dependent prisoners should be stabilised on licensed opiate substitute 
medication	for	a	minimum	of	five	days	to	enable	withdrawal	symptoms	to	be	
adequately controlled. This period also permits time for input from professionals 
from both within the community and the prison to inform a decision on whether 
to	proceed	to	detoxification	or	maintenance,	taking	into	account	the	wishes	of	
the	patient.	Detailed	assessment	and	care	planning	should	be	developed	over	
this	five-day	stabilisation	phase.	Effective	management	withdrawal	symptoms,	
within	the	context	of	a	minimum	of	five	days’	‘unrestricted’	observation	(with	
healthcare hatches open where they have been installed), may reduce the 
possibility of impulsivity associated with self-harming behaviours, and detect 
it more easily when it occurs.
5.2	 Patients	must	be	monitored	frequently	during	the	stabilisation	and	detoxification	
phases	to	ensure	that	symptoms	are	controlled	–	in	the	past	patients	have	died	
as	a	consequence	of	uncontrolled	vomiting	during	detoxification	in	prison.	If	this	
symptom persists beyond a period of 24 hours, the patient must be transferred 
to	an	outside	hospital.	Clinicians	need	to	be	cautious	where	the	patient	is	also	
on other prescribed medications such as tranquillisers and antidepressants, as 
these may precipitate central nervous system depression.
5.3 The four main purposes particular to prescribing methadone or buprenorphine 
in prison are:
•	 to	provide	a	gateway	to	community	substitute	treatment	for	those	who	
request this as a treatment option, assuming that this can be continued 
upon release back into the community;
•	 to	continue	community	methadone	or	buprenorphine	prescribing	
programmes	that	will,	in	turn,	be	re-established	following	release	(‘clinical	
throughcare’).	There	is	good	evidence	that	engagement	with	community	
specialist	drug	programmes	may	have	beneficial	effects	on	health	and	on	
offending	behaviour	(Mattick	et	al	2002);
•	 to	increase	tolerance	to	opioids,	which	reduces	–	but	by	no	means	eliminates	
–	the	risk	of	fatal	drug	overdose	upon	release	from	prison;
•	 to	reduce	self-harming	and	suicidal	behaviour	among	prisoners	with	a	
chronic drug dependence.
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5.4.1 Fatalities from methadone poisoning have been reported at doses as 
low as 20mg (Humeniuk et al 2000).	Non-opiate-dependent	individuals	
are at risk from doses as low as this, and the risk is exacerbated when the 
simultaneous	prescription	of	a	benzodiazepine	is	necessary.	Methadone	deaths	
tend to occur on the second or third day of treatment as a result of cumulative 
toxicity. These deaths occur as a consequence of inadequate assessment, failure 
to	confirm	previous	opiate	use	by	clinical	testing	for	drugs,	failure	to	confirm	
dependence	(such	as	treatment	in	the	absence	of	withdrawal	symptoms)	and	a	
lack of monitoring.
5.4.2	 Deaths	also	occur	as	a	result	of	concomitant	administration	of	other	drugs,	and	
drug	interactions	(BNF	2005).
5.4.3	 Such	tragedies	can	be	avoided	by	adherence	to	the	following	principles	of	
treatment:
• An adequate assessment of past history.
• An opioid-positive drug test result.
• Where there is doubt regarding the presence of dependence, a prescription 
is to be made only in the presence of objective signs of opioid withdrawal, 
which are: 
	 Sweating	 Lachrymation	and	rhinorrhea 
Yawning	 Feeling	hot	and	cold 
Anorexia  Abdominal cramps 
Tremor	 Nausea,	vomiting	and	diarrhoea 
Insomnia	and	restlessness	 Generalised	aches	and	pains 
Tachycardia,	hypertension	 Gooseflesh 
Dilated	pupils	 Increased	bowel	sounds				
(DH	1999)
•	 Gradual	dose	induction	in	increments	of	5	to	10mg	methadone	
(methadone	mixture,	1mg	in	1ml).
• Regular monitoring of the patient and, in the event of any sign of 
drowsiness, the withholding of the due dose of methadone and any other 
sedating medication pending reassessment.
•	 Supervised	consumption	of	prescribed	methadone	followed	by	the	
administration of at least 200ml water to reduce the potential for diversion.
5.4.4	 Methadone	has	a	variable	half-life	that	can	be	as	long	as	25	hours.	However,	a	
peak plasma level occurs at 2 to 4 hours after an oral dose. It is therefore wiser 
to commence stabilisation by the use of small doses spaced at intervals. This 
will help to prevent any initial accidental overdose in those who are susceptible 
or prove to be opiate naïve despite other tests and clinical signs to the contrary. 
Any indication of over-sedation/drowsiness must result in the nurse withholding 
methadone and other central nervous system depressant medicines pending 
medical reassessment.
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5.4.5	 Patients	should	be	subject	to	enhanced	observation	over	the	first	five	days	of	
methadone treatment. 
5.4.6 Risk factors: A large remand prison will need to assess and stabilise 200 or 
more new patients per month, a rate unknown in any other clinical substance 
misuse	setting.	Dose	induction	is	made	more	complicated	by	the	unusual	
dynamic of treatment being offered to an individual who has not requested it, 
the possibility of reduced tolerance following a break in consumption during 
police custody, observation inhibited by locked cell doors and the involvement 
of non-specialist clinical colleagues in the delivery of care.
5.4.7 To ensure patient safety within this context, methadone treatment 
programmes should be established through a process of dose induction. 
Initial doses of five to ten milligrams of methadone (1mg	in	1ml	mixture) 
are to be given, at least six hours apart. This rule also applies to the 
continuation	of	most	community	methadone	programmes	(see	section	8	
of this document for guidance on this area of practice).
5.4.8	 Where	the	above	regimen	appears	to	be	insufficient	to	manage	a	patient’s	
withdrawal,	a	substance	misuse	specialist	doctor	(primary	care	or	other	
background)	with	experience	in	local	(remand)	prison	practice	may	personally	
prescribe doses titrated against withdrawal in addition to this regimen, taking 
full account of the clinical risk factors described above.
5.4.9	 As	a	further	safeguard	for	the	patient,	and	as	a	means	to	minimise	the	potential	
for diversion and its attendant risks, the standard maximum recommended 
maintenance dose of methadone prescribed in prison is 40mg per day. 
The risk of fatality among naïve consumers above this dosage is the reason for 
this cautious and conservative approach. This recommendation will be reviewed 
in	the	light	of	future	clinical	findings	in	the	prison	setting.	
5.4.10	In	the	event	of	a	patient	continuing	to	experience	difficulties	at	40mg	
methadone, additional gradual titration of between 2 and 10mg per day may 
be indicated. This should only be prescribed under the guidance of a doctor 
with specialist addiction training1	who	has	had	70	hours’	experience	of	working	
in a prison of a similar category.2 A consultant in addiction psychiatry may 
also prescribe beyond 40mg once they have had the opportunity to familiarise 
themselves with practice in prison. Where prescriptions are substantially in 
excess of 40mg per day, divided dosing may be preferred.
1 That	is,	a	substance	misuse	specialist	doctor	(primary	care	or	other	background).	The	prison	
environment	presents	clinical	challenges	that	are	uncommon	in	other	settings	(see	section	2),	and	 
it is for this reason that practice experience in prison is required.
2	 In	view	of	the	significant	differences	in	the	operation	and	clinical	issues	encountered	between	remand	
(local)	and	training	prisons,	a	specialist	will	need	a	further	period	of	35	hours	to	become	familiar	with	
the issues of moving from one category of prison to another.
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5.5	 Stabilisation	of	opioid	withdrawal	may	be	achieved	via	buprenorphine.	Induction	
onto	buprenorphine	can	be	more	difficult	than	methadone	in	the	initial	phase	
of clinical management. It is therefore recommended that methadone should 
be	used	to	stabilise	the	opioid	withdrawal	of	all	dependent	patients.	Exceptions	
to	this	should	be	made	when	they	are	in	the	patient’s	better	interests.	These	
circumstances include:
•	 mild	cases	of	dependence	of	the	type	that	may	be	found	among	younger	
non-injecting heroin users;
•	 patients	who	declare	that	they	are	currently	prescribed	buprenorphine	
as part of a community programme;
•	 patients	who	express	a	preference	–	with	which	the	clinician	agrees	–	
for buprenorphine.
5.6 As a prelude to buprenorphine induction, liver function tests should be 
undertaken as a baseline. Treatment may commence prior to the receipt of 
any results. The patient must be advised that the partial agonist properties 
of buprenorphine may exacerbate rather than reduce withdrawal symptoms 
in	the	event	of	recent	or	current	opioid	use.	Patients	should	therefore	have	
been heroin-free for 12 hours and methadone-free for at least 24 hours prior 
to the initial dose of buprenorphine. They should also be exhibiting clear 
signs	of	opiate	withdrawal	(RCGP	2003).	Adjunctive	symptomatic	support	or	
additional buprenorphine may be required in the early stages of treatment. 
The	(sub-lingual)	administration	of	buprenorphine	demands	close	observation,	
as	diversion	(‘palming’)	of	tablets	is	a	common	problem.	Should	this	happen,	the	
buprenorphine programme should be discontinued and a clinically appropriate 
contingency	regimen	initiated	while	the	patient’s	treatment	is	reviewed	by	the	
clinical	team	and	a	treatment	intervention	appropriate	to	the	individual’s	need	
is introduced. It is particularly important that the alternative regimen is not 
deemed to be punitive.
5.7	 Equivalence	of	treatment	with	community	services	necessitates	that	active	
clinical management of the effects of withdrawal symptoms is provided. 
Adjunctive treatment of symptoms should be regarded as part of active 
clinical management. Vomiting and diarrhoea should, therefore, be managed 
by effective prescribing of carefully monitored antiemetic and antidiarrhoeal 
medication, with transfer to an outside hospital if symptoms are not adequately 
controlled within 24 hours. Where there is a clear indication earlier than this 
that dehydration or other medical complications such as a diabetic crisis are 
developing, transfer to an outside hospital should be arranged immediately. 
Intractable vomiting associated with withdrawal has been fatal on occasions 
in prison.
5.8	 Malnutrition,	anorexia,	hypothermia	and	hypoglycaemia	are	common	problems	
during	the	early	stages	of	drug	withdrawal.	Patients	must	have	access	to	food,	
naturally	sweetened	drinks,	adequate	fluids	and	extra	blankets	during	this	
phase.	Additional	food	(and	fluids)	at	night	are	necessary	during	the	recovery	
phase of withdrawal, when the appetite returns and sleep problems occur.
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5.9	 Insomnia is one of the most common symptoms of opiate, alcohol and 
benzodiazepine	withdrawal.	Protracted	sleep	loss	has	a	detrimental	effect	on	
thought, mood and behaviour. Insomnia should therefore be regarded as a 
potential risk factor for self-harm and suicide. It is recommended that a range of 
non-pharmacological interventions should be available to patients experiencing 
insomnia. Relaxation classes and other approaches to engender relaxation may 
be	of	benefit.	In-cell	radio	or	television	should	be	provided	but	not	charged	
for	during	the	detoxification	phase.	Prescription	of	hypnotics	should	not	be	
necessary during the stabilisation phase. If, as reduction progresses, insomnia 
becomes a problem, a short-acting hypnotic may be prescribed for a limited 
period and reviewed according to patient response. It should be borne in mind 
that these drugs are in themselves dependence forming and liable to be abused 
in the prison setting. The possibility of interaction between opiate agonists and 
hypnotics should also be considered when deciding on treatment.
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6 Management of opiate overdose
6.1 Opiate overdose is characterised by:
•	 constricted	(pinned)	pupils	(although	dilation	can	occur);
•	 respiratory	depression/cyanosis;
•	 pulmonary	oedema	(frothing	from	the	lung);
•	 sweating;
•	 hypotension	and	bradycardia;
•	 unconsciousness.
6.2 Opiate overdose should be treated by resuscitation with oxygen.
6.3 Emergency	administration	of	0.8	to	2mg	naloxone	should	be	given	I/V	or	I/M	
and repeated as necessary on account of its short half-life relative to heroin 
and methadone. 
6.4 In an emergency, naloxone may be administered by parenteral injection 
by any competent member of the healthcare team (HMSO 2005).
6.5 An emergency ambulance transfer to an outside hospital must be arranged. The 
patient must be observed closely for 24 hours following return from hospital, as 
a secondary episode of respiratory depression can follow the discontinuation of 
naloxone treatment.
6.6 In the event of a suspected buprenorphine overdose, substantially more 
naloxone may be required.
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7 Opiate agonist maintenance
7.1 Both methadone and buprenorphine maintenance are at present infrequently 
provided	in	English	and	Welsh	prisons.	Community	maintenance	programmes	
should be continued in prison following stabilisation, unless the patient or 
the existing community prescriber indicate otherwise. To ensure continuity of 
treatment upon release, referral to community services should be made through 
the	CARAT	team.	Where	there	is	a	need	to	secure	urgent	continuity	of	clinical	
management	out	of	CARAT	office	hours,	it	is	the	responsibility	of	the	prison	
healthcare	team	to	ensure	that	a	community	prescriber	is	notified	of	a	patient’s	
discharge from prison. 
7.2	 For	detailed	direction	on	the	prescribing	of	methadone,	see	section	5.4	of	this	
document.
7.3	 The	recommended	upper	dose	of	buprenorphine	is	8	to	16mg	per	day.	In	
exceptional circumstances, this may be increased to a maximum of 32mg 
where buprenorphine is a single agent. Where there is concurrent prescribing 
of	benzodiazepines	(or	other	central	nervous	system	sedative	drugs),	there	
is a risk of respiratory depression, and prescribing should therefore take this 
into account for both buprenorphine and methadone.
7.4	 Patients	whose	withdrawal	symptoms	have	been	stabilised	using	methadone	
may be transferred to buprenorphine through the staged reduction of their 
methadone	to	20mg	per	day.	Following	a	break	of	at	least	24	hours,	and	upon	
observation of signs of opiate withdrawal, buprenorphine may be introduced 
at a dose of 4mg per day on day one. 
7.5	 Methadone	or	buprenorphine	maintenance	should	be	linked	to	ongoing	
support, including educational and occupational rehabilitation. In many 
instances, after a period of maintenance individuals will elect to withdraw. 
They should be permitted to do so at a rate with which they feel comfortable 
and that is manageable on an outpatient basis. As a patient nears their date 
of release, any reduction achieved should be reviewed, with the patient being 
made	aware	that	a	dose	that	has	proven	adequate	in	prison	may	be	insufficient	
when	they	are	released.	Consideration	may	then	need	to	be	given	to	raising	the	
dose of methadone back to the previous maintenance level before discharge. 
Some	individuals	will	elect	to	withdraw	completely	to	enable	them	to	pursue	
a drug-free rehabilitation, either in prison or back in the community. 
7.6 All individuals with a history of dependent opiate use who are received into 
custody	on	a	short	sentence	(ie	up	to	approximately	26	weeks)	should	be	given	
the option of continued maintenance following stabilisation. A community 
prescriber should be located to ensure that treatment continues upon release. 
An	absence	of	injecting	drug	use	–	a	pattern	that	is	common	among	opiate-
dependent	members	of	the	black	and	minority	ethnic	community	–	should	not	
preclude	entry	to	a	maintenance	programme	(Sangster	et	al	2002).	Where	there	
is a high likelihood of a patient returning to injecting opiate use upon release, 
but no community prescribing services can be accessed, maintenance should 
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be provided on the grounds of post-release overdose protection. Random 
clinical drug testing for illicit drug use should form part of any maintenance 
programme. 
7.7 A chronic opiate user who is received into custody on remand should also be 
offered a maintenance methadone prescription; a community prescriber should 
be located for that individual. Where a period of remand extends beyond 13 
weeks,	members	of	the	drug	treatment	(ie	CARAT	and	healthcare)	team	should	
review the maintenance programme. As with sentenced drug users, where there 
is a high likelihood of a patient returning to injecting opiate use upon release, 
but no community prescribing services can be accessed, maintenance may be 
provided on the grounds of post-release overdose protection.
7.8	 For	guidance	on	the	continuation	of	community	methadone	programmes,	
see	section	8.
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8  Continuation of methadone  
programmes
8.1	 To	ensure	safety,	patients	arriving	in	prison	who	are	currently	receiving	a	
community methadone prescription should be treated in accordance with the 
standard	dose	induction	regimen	(as	per	section	5.4	above).
8.2	 Continuation	of	methadone	programmes	at	the	existing	community	dose	may	
only be provided in circumstances that meet all of the following criteria:
•	 The	patient	is	receiving	methadone	under	supervised	consumption	
conditions.
•	 The	patient	has	been	receiving	methadone	regularly	for	the	previous	
seven days.
•	 The	patient	last	had	their	full	supervised	dose	of	methadone	within	the	
past	48	hours.
•	 The	patient’s	treatment	details	have	been	verified	with	the	prescribing	
doctor and the supervising pharmacist.
8.3	 In	cases	that	meet	all	of	the	above	criteria,	the	following	regimen	should	
be followed:
• First night: Assuming the patient has had their methadone on the day of 
arriving in prison, no further doses will be given. The patient should be drug 
tested and must be positive to methadone metabolites.
•	 Next day (day 2):	Confirmation	needs	to	be	obtained	from	the	prescribing	
doctor/drug service of the dose and duration of methadone treatment. 
Where the location of the community pharmacist is unknown, the chief 
pharmacist within a primary care trust may be able to identify the correct 
practitioner. A brief description of the patient should be sought from the 
pharmacist	to	verify	correct	identity.	(To	protect	patient	confidentiality,	
mechanisms	should	be	put	in	place	to	ensure	pharmacists	can	confirm	the	
identity of the healthcare team they are talking to before giving out this 
information.)	As	a	further	safeguard,	it	is	recommended	that	the	first	two	
days’	doses	of	methadone	be	evenly	divided	in	two,	with	at	least	six	hours’	
gap between the supervised administration of each dose.
8.4	 In	view	of	the	universal	use	of	supervised	consumption	of	methadone	in	prisons,	
it is anticipated that patients on methadone programmes transferring between 
prisons	will	meet	all	the	criteria	set	out	in	section	8.2	above.	In	such	cases,	
treatment should be continued at the existing dose.
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9 Detoxification
Opiate
9.1	 In	respect	of	opiate	detoxification,	the	decision	as	to	when	and	by	which	
pharmaceutical	agent	detoxification	will	be	provided	should	be	made	on	the	
basis of a combination of three factors:
•	 the	patient’s	severity	of	dependence;
•	 the	patient’s	wishes;
•	 the	opinion	of	practitioners	involved	in	the	patient’s	care,	both	in	the	
community and within the prison.
9.2	 Following	a	minimal	five-day	stabilisation	on	either	of	the	above	two	agonists,	
detoxification	should	routinely	be	for	a	minimum	of	14	days	if	withdrawing	
from a short-acting opiate but longer if withdrawing from methadone. 
Detoxification	will	often	need	to	be	for	21	days	or	more	if	methadone	has	
been	used	regularly	prior	to	arrest.	Dosage	should	be	adjusted	as	needed,	
in response to signs and symptoms of withdrawal. Overall, it is best to have 
minimum	standard	withdrawal	periods,	which	can	then	be	extended.	However,	
in the context of severe polydrug and alcohol dependence, a more graduated 
individual approach will be necessary; the methadone regimen should remain 
stable	while	the	alcohol	detoxification	is	taking	place.	Such	management	
can assist in reducing the risk of impulsive self-harming behaviour.
9.3	 For	patients	who	have	been	stabilised	on	buprenorphine,	a	buprenorphine	
detoxification	involves	a	gradual	reduction	in	doses	over	the	course	of	at	
least	two	weeks.	For	patients	who	have	been	stabilised	on	methadone,	a	
buprenorphine	detoxification	should	not	be	commenced	until	the	patient	has	
reduced to 20mg methadone per day, with a minimal gap of 24 hours between 
the last dose of methadone and the initial 4mg dose of buprenorphine. The 
patient should be reviewed two to three hours later. If withdrawal symptoms 
have been precipitated, symptomatic medication should be prescribed. 
Following	full	conversion	to	buprenorphine,	a	minimum	14-day	reduction	
regimen should be initiated.
9.4	 Following	the	five-day	stabilisation	onto	an	appropriate	level	of	either	of	
the	above	agonists,	patients	may	elect	to	undergo	detoxification	using	a	
non-opiate	agonist	(ie	lofexidine).	For	patients	who	have	been	stabilised	on	
methadone,	there	should	be	a	minimum	break	of	24	hours	between	their	final	
dose of methadone and their initial dose of lofexidine. To control withdrawal, 
detoxification	should	ordinarily	commence	at	200	micrograms	twice	a	day,	
increased daily as necessary in steps of 200 to 400 micrograms to a maximum 
of 2.4mg. This regimen may need to be adjusted in response to withdrawal 
symptoms, with higher doses needed by some patients at the early stages of 
opiate withdrawal. Lofexidine may cause bradycardia or hypotension in some 
patients. Blood pressure and pulse rates must therefore be checked prior to 
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the administration of each dose, two hours after the initial dose and daily as the 
dose	is	increasing	for	at	least	the	first	72	hours	of	the	detoxification	regimen	
and for longer if there are abnormalities. If the patient shows indications of 
low blood pressure or slowed pulse, they should be advised to rest with feet 
elevated, and monitored until improvement is observed.
9.5	 Practitioners	should	be	aware	that	whatever	the	duration	of	detoxification,	
withdrawal symptoms will frequently persist beyond the cessation of all 
medication.	It	is	important	to	provide	support	for	individuals	in	the	first	few	
days after stopping an opiate agonist; at this time some individuals will require 
symptomatic	relief,	which	may	include	the	use	of	lofexidine	(with	blood	pressure	
and pulse monitored as above). Where individuals are transferred from a 
withdrawal management unit to an ordinary, residential location, practitioners 
should ensure that the residential manager is aware of the increased risk and 
the need for their staff to provide support to the prisoner at this time.
9.6	 Methadone	or	buprenorphine	should	never	be	prescribed	to	a	patient	who	has	
produced a negative opiate-test sample, unless they exhibit clear objective signs 
of	opiate	withdrawal	or	there	is	evidence	of	a	confirmed	prescription.	In	the	
absence of either of these, it is preferable to use a non-opiate medication such 
as lofexidine. 
Alcohol
9.7	 Assessment	for	alcohol	withdrawal	should	begin	in	reception,	as	the	first	
signs of withdrawal commence six to eight hours after an alcohol-dependent 
individual’s	last	drink.	Tremor	is	the	earliest,	most	common	and	easily	
recognisable	sign;	seizures	can	begin	in	the	first	24	to	48	hours.	
9.8	 Alcohol	detoxification	should	be	managed	with	chlordiazepoxide	from	the	first	
night	of	custody.	This	should	begin	in	reception.	Common	features	of	alcohol	
withdrawal include sweating, tremors, nausea, vomiting, hypertension  
and tachycardia.
9.9	 A	percentage	of	patients	are	at	risk	of	more	serious	complications,	such	as	
delirium tremens and seizures. These two conditions are potentially fatal, so 
it is therefore essential that all prisoners who give a history of heavy alcohol 
consumption prior to their arrival in custody are assessed and, if necessary, 
should	begin	a	chlordiazepoxide	detoxification	regimen	in	reception	in	
accordance	with	PSO	3550	(HM	Prison	Service	2000).	When	making	an	
assessment of alcohol dependence, it is important that the level of alcohol 
consumption is explored and details of the type of alcohol noted, including 
brand	and	–	where	possible	–	strength.	An	estimation	of	the	units	can	be	made	
from	this	information.	Extra-strong	beers/lagers	and	ciders	contain	4	units	per	
can,	and	an	average-strength	can	contains	2.5	units.	Malnutrition,	particularly	
thiamine	deficiency,	can	cause	neurological	damage.	All	patients	who	undergo	
alcohol	detoxification	should	be	routinely	prescribed	200mg	thiamine	daily	for	
a	period	of	28	days.	If	a	patient	does	not	require	formal	alcohol	detoxification	
but has a recent history of heavy drinking, they should still receive thiamine 
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as	a	precautionary	measure.	Patients	will	also	require	sufficient	fluids	to	
reverse	potential	dehydration,	and	adequate	calorific	foods	to	protect	against	
hypoglycaemia.
9.10	 Where	there	is	a	previous	history	of	alcohol	withdrawal	seizures,	the	
chlordiazepoxide	regimen	will	need	to	be	paced	to	take	account	of	this.	For	
those who have a diagnosis of epilepsy, anticonvulsant medication should 
be	continued,	and	may	need	to	be	increased	during	the	first	14	days	of	
withdrawal.
9.11	 It	is	important	that	these	individuals	are	monitored	for	the	first	seven	days	
of their management, as they may suddenly deteriorate or may suffer an 
epileptic seizure.
9.12	 In	the	treatment	of	concurrent	opiate	and	alcohol	dependence,	no	reduction	
in	the	opiate	agonist	should	be	attempted	until	the	alcohol	detoxification	
is complete.
 Please note that if a patient shows any signs of alcohol withdrawal 
during detoxification, additional doses of chlordiazepoxide should be 
given and its effectiveness observed. Should a patient’s condition fail 
to stabilise, their transfer to a general hospital must be effected as a 
matter of urgency, as uncontained alcohol withdrawal is a potentially 
fatal condition.
Benzodiazepine
9.13	 Assessment	of	benzodiazepine	dependence	should	be	informed	by	self-reported	
history,	confirmed	prescribing	history	(if	applicable),	withdrawal	monitoring	and	
drug	testing.	Please	note	that	as	benzodiazepine	withdrawal	may	take	more	
than 72 hours to set in, a negative drug test result should not automatically 
preclude	the	prescription	of	a	benzodiazepine	detoxification.	The	sudden	
cessation of benzodiazepines can lead to a recognised withdrawal state, where 
there is risk of seizures and other potential medical problems. These include 
psychosis, anxiety states, insomnia, nausea, headaches and tremor. 
9.14	 Withdrawal	prescribing	(ie	detoxification)	should	be	initiated	on	the	day	of	
admission where there is a history of benzodiazepine dependence from either a 
prescription or regular street use. Where clinical assessment indicates a previous 
history	of	regular	benzodiazepine	use	sufficient	in	dose	and	(in	particular)	
duration	to	suggest	dependency,	a	benzodiazepine	detoxification	regimen	
should	be	prescribed.	Each	prison	should	have	treatment	guidelines	for	the	
management	of	benzodiazepine	withdrawal	in	line	with	DH	(1999)	guidelines.	
These	should	be	developed	in	conjunction	with	an	NHS	specialist.
9.15	 In	cases	of	co-dependency	on	any	combination	of	alcohol,	opiates	and	
benzodiazepine, more than one reduction regimen may be required, with 
additional caution necessary due to the interaction of these drugs.  
A substantial level of clinical experience within prisons has shown that  
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low-dose	chlordiazepoxide	detoxification	for	alcohol	withdrawal	and	a	low-dose	
diazepam regimen for concurrent benzodiazepine dependence can be safely 
prescribed together, although there are limits to the levels of the combination. 
Beyond the acute alcohol withdrawal phase, the total diazepam-equivalent 
prescription should not exceed 30mg per day where a concurrent opiate 
substitute is being prescribed. 
9.16	 To	reduce	the	risk	of	over-sedation,	the	diazepam	should	be	prescribed	in	
divided doses until a level of 20mg per day is reached. The benzodiazepine 
withdrawal	is	then	gradual	at	a	rate	of	no	more	than	2mg	per	week	(BNF	
2005,	DH	1999).	Where	it	appears	that	a	patient	who	has	been	prescribed	a	
benzodiazepine reduction programme may not be benzodiazepine dependent, 
a	substance	misuse	specialist	doctor	(primary	care	or	other	background)	
with experience in prison practice should review the reduction regime. In 
view of the possibility of oversight occasioned by the very high admission 
rates to withdrawal management units, it is recommended that alcohol and 
benzodiazepine	detoxification	regimens	be	prescribed	separately,	utilising	
chlordiazepoxide and diazepam respectively. Alternatively, clinicians may wish 
to combine these two regimens using an increased level of chlordiazepoxide 
for	the	first	seven	days	to	cover	both	withdrawal	regimens.	There	is	a	need	to	
ensure that the longer-term prescribing required for benzodiazepine reduction 
is	in	place	as	the	alcohol	withdrawal	phase	is	finishing.	Benzodiazepine	
dependence and withdrawal can be associated with serious suicide and self-
harming behaviours, and should be managed accordingly with due caution, 
which may in certain instances require a slower reduction than indicated above.
9.17	 Where	opiate	agonist	maintenance	is	being	offered,	detoxification	from	
benzodiazepines may be undertaken as described above, but where concurrent 
detoxification	from	opiates	and	benzodiazepines	is	being	undertaken,	a	more	
cautious approach to both will be required.
9.18	 Patients	with	a	confirmed	history	of	epilepsy	will	require	cautious	rates	of	
reduction for benzodiazepine dependence, informed by ongoing monitoring. 
An increase in the levels of any currently prescribed anticonvulsant medication 
may be required.
9.19	 Where	there	are	concerns	that	a	patient	may	be	diverting	prescribed	diazepam	
tablets, clinicians should consider the use of the alternative liquid formulation. 
9.20	 All	aspects	of	clinical	care	of	a	patient	with	a	substance	misuse	problem	
should be provided in accordance with evidence-based practice and within the 
context	of	the	prison’s	clinical	governance	framework.	Clinical	supervision	is	an	
important means of supporting high-quality clinical practice.
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10  Management of stimulant  
withdrawal
10.1 A prisoner who has a substance misuse problem but does not require clinical 
management	of	this	problem	should	be	admitted	to	the	First	Night	Centre/
Induction	Centre	in	local	prisons	where	this	provision	exists.	
10.2	 Prisoners	with	substance	misuse	problems	who	are	located	outside	of	the	
withdrawal	management	unit	should	be	observed	for	fluctuations	in	mood	
or	behaviour.	Among	this	group	of	prisoners	will	be	stimulant	users	(including	
‘crack’	users).	Withdrawal	from	stimulants	can	cause	marked	swings	in	
mood, leading to potential acts of violence towards self or others. A short 
but profound depression is a recognised withdrawal symptom, which may 
necessitate treatment. To reduce the risks associated with isolation, the prison 
regime should ensure that optimum time is available for purposeful activities.
10.3	 Cocaine	use	is	associated	with	a	number	of	serious	medical	problems,	
particularly cardiovascular complications, including cardiac arrhythmias and 
myocardial infarction. Acute cocaine use increases the risk of stroke secondary 
to	arterial	vasospasm,	thrombosis	or	hypertension.	Sudden	death	occasioned	by	
intracranial bleeding/thrombosis or cardiac arrest appears to be an increasing 
risk among young adults abusing crack. It is recommended that patients 
reporting recent heavy stimulant use and who test positive on admission to 
either cocaine or amphetamines are admitted to the withdrawal management 
unit, where neurological observations and blood pressure monitoring for signs 
of	hypertension	should	be	carried	out	for	the	first	three	days	of	custody.	Any	
abnormalities would warrant full medical assessment, and in the event of 
continued concern, the patient should be transferred to an outside hospital. 
Particular	attention	should	be	given	to	any	reports	of	headache	or	dizziness	
during this period. Where there is evidence of agitation or volatility in those 
withdrawing from stimulants, consideration may be given to short-term 
prescribed management of some of the symptoms of withdrawal. 
10.4	 Dual	diagnosis	is	not	uncommon	among	substance	misusers	in	prison.	The	 
1997	Office	for	National	Statistics	psychiatric	morbidity	study	(Singleton	et	al	
1997)	identified	five	main	mental	health	disorders.	Some	54%	of	male	remands,	
44%	of	males	sentenced,	61%	of	female	remands	and	42%	of	females	
sentenced were substance misusers and had three or more of these disorders.
10.5	 An	underlying	serious	mental	health	problem	(such	as	schizophrenia)	may	
appear in a newly drug-free phase. A full mental health assessment should be 
considered for any prisoner demonstrating signs of these problems. A full range 
of	supportive	resources	(eg	NHS,	mental	health	in-reach	services,	Listeners	and	
CARATs)	should	be	available	within	the	establishment	to	meet	the	needs	of	 
this	group	of	prisoners.	Concerns	for	a	prisoner’s	safety	as	a	consequence	of	
their	mental	distress	should	result	in	the	activation	of	the	prison	service’s	 
multi-disciplinary	risk-management	process	(ACCT	Plan	or	F2052SH).
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10.6 The needs of stimulant users coming into prison should be addressed by their 
inclusion	in	the	28-day	psychosocial	intervention	(see	section	15),	including	
access	to	specialist	stimulant	groups	and	relaxation	classes.	Continuity	of	service	
is central to good outcomes for stimulant users. Introduction to any community 
stimulant	services	within	the	prisoner’s	home	area	should	therefore	be	provided.
Clinical Management of Drug Dependence in the Adult Prison Setting
 Page 29
11  Continuity of treatment
11.1	 Consideration	must	be	given	to	the	needs	of	patients	receiving	prescribed	
management of drug dependence on a day when they are due to leave prison 
custody to attend court. All remand prisoners should receive their opioid 
substitute medication in the morning, prior to any attendance at court, to 
restrict the emergence of withdrawal symptoms if they are released later in 
the day. Local protocols should be negotiated between the prison, escort 
contractors and court administrators for the secure administration of medicines 
that	are	prescribed	in	more	frequent	doses.	The	relevant	CJIT	needs	to	be	
notified	at	the	earliest	opportunity	when	a	patient	who	is	part	of	the	Drug	
Interventions	Programme	and	is	receiving	clinical	management	of	substance	
misuse is due to appear in court.
11.2   The period immediately following release is a time of considerable vulnerability. 
For	patients	leaving	prison	with	existing	prescribed	management	of	their	
substance misuse problem, contact should be established with a community 
service at the earliest opportunity, so that an appointment may be made 
following	release.	Close	working	between	the	clinical	and	CARAT	teams,	the	
local	CJIT	or	relevant	community	treatment	provider	is	central	to	the	securing	
of	good	integrated	care.	Where	a	patient	leaves	prison	on	a	Friday,	they	may	
not be seen until early the next week. In such circumstances a community 
pharmacist should be located to provide an interim dispensing service. In the 
event of no pharmacy being available, a risk assessment should be conducted 
to help determine how much take-home medication should be issued to the 
individual.	Routinely	it	is	recommended	that	three	days’	take	home	medication	
is given. In the case of methadone this should be given in three separate bottles. 
On	a	bank	holiday	weekend,	further	days’	medication	may	be	required.
11.3	 Provided	that	they	are	medically	stable,	patients	who	are	on	a	maintenance	
opioid programme may transfer to a training prison. The receiving prison should 
continue treatment in line with the criteria set out in section	8 of this document.
11.4	 Patients	on	a	maintenance	programme	can	transfer	to	open	conditions	after	
28	days	of	commencement	of	clinical	management.	Again,	treatment	should	
be	continued	in	accordance	with	section	8	of	this	document.	
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12  Administering of medications 
and nursing observation
12.1	 There	should	be	a	minimum	period	of	five	days’	observation	of	patients	 
who are undergoing clinical management by nursing staff, and longer if 
abnormalities	are	detected.	Wherever	possible	this	should	be	‘unrestricted’	with,	
where	they	are	installed,	healthcare	hatches	open	in	doors	where	detoxification	
is undertaken. A protocol should be in place to determine the circumstances 
when hatches may be closed. It is necessary to observe patients during the early 
phase	of	withdrawal	either	for	withdrawal	symptoms	such	as	fitting,	vomiting	
or distress or for side effects of medication such as a sudden reduction in 
blood pressure.
12.2	 Staff	should	supervise	the	consumption	of	every	dose	of	methadone	or	
buprenorphine. All additional non-opioid medication should be consumed 
under	supervision	for	at	least	the	first	10	days	of	detoxification,	to	monitor	
efficacy	and	to	allow	doses	to	be	adjusted	accordingly.	To	enhance	control	
of	diversion	it	is	further	recommended	that	all	doses	of	diazepam	(or	
other benzodiazepine-based medication) be prescribed for supervised 
consumption only. 
12.3	 Methadone	or	buprenorphine	should	be	administered	by	a	registered	nurse	
or pharmacist. A second member of staff should be present to act as a witness. 
Before administering methadone or buprenorphine, nursing staff must:
•	 check	the	identity	of	the	patient;
•	 ensure	the	patient	is	fully alert and responding appropriately, and that 
there are no signs of drowsiness/collapse, slurred speech, droopy eyelids 
or lowering of blood pressure;
•	 consider	whether	there	are	any	other	reasons	to	suspect	additional	
illicit drug use.
12.4 In the event of uncertainty regarding any of the above, the nurse must 
withhold the methadone or buprenorphine and other sedating 
medication, observe the patient, monitor blood pressure, notify a doctor 
and test for drug use.
12.5	 Prison	should	have	protocols	for	the	management	of	drug	overdosage,	
including overdose of methadone.
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13 Complex needs: dual diagnosis
13.1	 Rapid	withdrawal	from	drugs	of	dependence	can	upset	a	patient’s	mental	
equilibrium, heightening their risk of impulsive self-destructive behaviour. It is 
therefore recommended that a patient coming into custody with complex needs 
should be provided with clinical treatment to stabilise their withdrawal from 
opiate	or	benzodiazepine	dependence.	Consideration	should	be	given	at	this	
early stage to the indication for opiate maintenance. 
13.2	 Details	of	the	planned	care	provided	by	the	patient’s	community	mental	health	
team	(CMHT)	and	dual	diagnosis	services	prior	to	custody	should	be	established.	
The	patient’s	informed	wishes	and	the	advice	of	community	providers	should	
be taken into account when clinical substance misuse care is planned. If 
detoxification	is	the	preferred	action,	the	opinion	of	the	Royal	College	of	
Psychiatrists	(Royal	College	of	Psychiatrists	2002)	is	that	a	gradual	reduction	
programme	would	be	in	the	patient’s	best	interests.	
13.3 An integrated approach is recognised as the best way of managing patients 
with	complex	needs.	This	involves	active	consultation	between	CARAT,	clinical	
substance misuse, primary healthcare and mental health teams. 
13.4 All patients with a serious mental illness should be managed within the 
Care	Programme	Approach	(CPA).	This	system	requires	the	involvement	of	all	
significant	parties,	including	the	patients	themselves,	their	families,	community	
services,	in-prison	services	and	(where	the	patient	is	located	on	ordinary	
location) residential staff.
13.5	 Patients	received	into	prison	with	an	existing	CPA	will	have	that	CPA	continued.	
In these cases, the mental health team within the establishment will discuss with 
the	CMHT	which	service	will	provide	a	care	co-ordinator.
13.6	 For	patients	who	have	no	history	of	mental	health	treatment	but	who	
demonstrate symptoms of serious mental illness, the mental health team 
within	their	establishment	will	need	to	initiate	the	CPA.	Representation	should	
be	sought	from	the	patient’s	home	mental	health	service	(CMHT),	and	this	
community team will be involved in the planning of all subsequent care. 
13.7	 While	in	prison,	where	there	is	less	ready	access	to	illicit	drugs,	a	patient’s	
mental state may appear quite stable. The release care plan needs to take into 
account the previous history of substance misuse, as the patient is liable to 
return	to	drug	taking	upon	release.	Similarly,	any	previous	history	of	substance	
misuse must also be considered when a patient is transferred to another prison.
13.8	 Some	detoxification	patients	may	show	no	signs	of	mental	disorder	until	they	
reach an advanced stage in their withdrawal programme. This may be a delayed 
response to the withdrawal from substances that have antipsychotic properties; 
opiates, benzodiazepines, alcohol and even stimulants may have the capacity to 
limit the symptoms of psychosis experienced by individuals with serious mental 
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health problems. Timely and measured clinical intervention would help to 
contain these breakthrough problems. 
13.9	 Further	guidance	on	the	management	of	patients	with	a	dual	diagnosis	in	the	
prison setting will be published shortly. 
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14  Clinical management during  
pregnancy
14.1	 Protocols	should	be	agreed	locally	between	the	community	obstetric	services,	
the prison clinical team and the local specialist drug service on the management 
of a pregnant woman who is heroin or methadone dependent.
14.2 The aim of these will be to ensure a safe pregnancy with minimal withdrawal 
in	the	neonate.	Upon	arrival	in	prison,	all	pregnant	women	should	be	stabilised	
on	methadone	for	a	minimum	period	of	two	weeks.	Drug	dependency	may	
be associated with amenorrhoea; therefore, a pregnancy test may need to 
be undertaken during assessment. A referral to the drug liaison midwife 
should be made immediately (assuming	that	the	woman	wishes	to	continue	
with the pregnancy) and probation services advised, as they will then contact 
the community social services department. If there are no existing antenatal 
records,	a	dating	scan	must	be	arranged	to	confirm	the	gestation	of	pregnancy.	
No	changes	to	treatment	should	be	made	until	this	is	known.	
14.3	 In	accordance	with	DH	(1999)	guidelines,	low-dose	methadone	maintenance	
should be offered, although a slow reduction in the mid-trimester may be 
offered	if	the	patient	prefers.	There	should	not	be	any	reduction	in	the	first	
trimester,	and	maintenance	is	preferred	in	the	third	trimester.	Some	patients	
require an increase in methadone in the third trimester, and it may be necessary 
to provide this in daily divided doses. Where patients insist on continuing with 
a reduction regimen in the third trimester, this should be paced as slowly as 
possible: ideally no more than 1mg of methadone per week.
14.4	 Methadone	maintenance	in	place	at	the	time	of	delivery	should	be	continued	
indefinitely	in	the	postnatal	period,	both	for	women	who	remain	in	prison	with	
their babies and for those who are separated. This is in an attempt to stabilise 
the mother at this very vulnerable time, and then to allow her to re-engage with 
a local treatment agency upon release. (A	community	prescriber	must	be	found	
prior	to	the	patient’s	release,	and	these	arrangements	should	be	made	well	in	
advance to ensure continuity of treatment and support upon release.) If the 
patient wishes to reduce her methadone in the postnatal period and there are 
otherwise good supports, this can of course be undertaken, but with caution. 
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15  Open psychosocial support 
intervention
15.1	 Detoxification	and	maintenance	programmes	are	two	of	the	key	treatment	
modalities under models of care and therefore can be seen as interventions in 
their	own	right.	However,	they	are	also	a	gateway	into	a	treatment	journey	for	
those clients who require ongoing psychosocial treatment/support to remain 
drug-free/stable. 
15.2 Both pharmacological interventions and psychosocial treatment are more 
effective when they work together in an integrated and harmonised manner. 
15.3	 The	Drug	Strategy	Unit	document	Integrated Drug Treatment System: the first 
28 days: psychosocial support	(National	Offender	Management	Service	2006)	
describes how psychosocial services will be delivered for problematic drug users 
during	the	first	28	days	of	custody	under	the	Integrated	Drug	Treatment	System,	
as funding permits. The main aim of the psychosocial intervention is to provide 
a	28-day	structured	care	package	of	psychosocial	support	for	prisoners	with	
problematic drug use which:
•	 complements	clinical	interventions;
•	 takes	into	account	previous	treatment	in	the	community	or	custody;
•	 provides	a	platform	for	longer-term	drug	treatment	in	prison	and	on	release.	
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16 Naltrexone
16.1  The option of naltrexone treatment should be available where requested and 
clinically	indicated.	Naltrexone	may	be	prescribed	following	detoxification	to	
those who require assistance to sustain abstinence from opiates
16.2	 Naltrexone	treatment	should	begin	at	least	five	days	prior	to	release	from	prison.	
A doctor who is willing to continue prescribing in the community will need to  
be	identified	before	treatment	is	initiated.	Naltrexone	alone	will	probably	be	 
insufficient	to	prevent	a	return	to	heroin	addiction	–	it	should	be	offered	in	
conjunction with a community programme that addresses the social and 
psychological implications of drug dependence.
16.3 A liver function test is required prior to commencement of treatment. A full blood 
count	test	is	additionally	recommended.	Serum	aspartate	aminotransferase	(AST)	
levels may increase during naltrexone therapy. If a baseline liver function test 
shows	AST	at	a	level	two	or	more	times	higher	than	normal,	naltrexone	treatment	
should not be commenced. It is recommended that patients with baseline 
abnormalities	should	have	their	bloods	monitored	every	two	weeks	for	the	first	
six weeks of treatment, and once every month thereafter. It is recognised that this 
will ordinarily be in the post-release period and consequently the responsibility of 
a community prescriber.
16.4 If a patient decides to cease their naltrexone treatment, they must be strongly 
advised	that	they	will	have	lost	all	of	their	former	tolerance	to	opioids.	Careful	
advice will therefore be required to stress that any return to heroin use must 
be	at	a	considerably	lower	dose	than	at	the	height	of	the	patient’s	previous	
consumption. While stressing the inherent risk in return to any form of heroin 
use, the danger of direct return to intravenous opiate use should be particularly 
emphasised. 
16.5 As naltrexone will block any opiate analgesia, it is not indicated for patients who 
have chronic pain problems or are awaiting surgery. All patients commencing 
naltrexone	treatment	should	be	issued	with	a	medical	alert	card.	Patients	should	
be cautioned against any attempt to overcome the blocking effect of naltrexone 
by the use of increasing amounts of heroin.
16.6 A patient who is physically dependent on opioids at the commencement of a 
course of naltrexone will be thrown into immediate and profound withdrawal 
upon	taking	their	first	tablet.	To	avoid	any	likelihood	of	this	occurrence,	it	is	
recommended that:
•	 naltrexone	treatment	should	not	be	initiated	until	a	patient	is	7	days	clear	
of	heroin	or	(because	of	its	greater	half	life)	14	days	clear	of	methadone;
•	 a	drug	screen	should	confirm	this	opioid-free	status;
•	 treatment	should	commence	with	a	naloxone	‘challenge’.
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16.7 A naloxone challenge involves the intravenous injection of 0.2mg of naloxone, 
followed by 30 minutes of observation. Any undeclared use of opioids 
that may have escaped detection via drug screening will become apparent. 
The withdrawal effects that this challenge can provoke are less acute and 
uncomfortable than those that would be engendered by oral naltrexone.  
If the patient shows no discernible reaction to this challenge, a second injection 
of 0.6mg should be given, and the patient closely observed for a further 
30 minutes for signs and symptoms of opioid withdrawal. If no withdrawal 
effect becomes apparent, the patient is now clear to begin taking naltrexone. 
Following	a	successful	naloxone	challenge,	an	initial	observed	dose	of	25mg	
(half	a	tablet)	should	be	given.	If	there	is	no	discernible	reaction,	the	regular	
daily regimen of 50mg can commence on the following day. 
16.8	 In	circumstances	where	venous	access	is	poor	but	the	clinician	is	confident	
that the patient is drug-free and has been so for the required preceding period 
(ie	7–14	days,	dependent	on	the	type	of	opioid	last	used),	the	clinician	may	 
give naltrexone as an oral challenge. The patient should be given a quarter 
tablet	(12.5mg)	of	naltrexone	and	observed	for	two	hours	with	a	further	 
follow-up outpatient appointment later the same day. If the patient demonstrates 
no discernible signs of withdrawal, he or she may be given a half tablet of 
naltrexone	(25mg)	on	the	following	day.	If	again	no	problems	occur,	the	full	 
dose	(50mg)	of	naltrexone	can	commence	the	following	day.
Clinical Management of Drug Dependence in the Adult Prison Setting
 Page 37
17  Black and minority ethnic substance 
misusers
17.1	 Access	to	prison	drug	services	by	black	and	minority	ethnic	(BME)	prisoners	is	
often	very	limited.	Clinical	teams	should,	therefore,	monitor	the	utilisation	of	
their service by this particularly disadvantaged group, as part of a process of 
monitoring service uptake by members of all diverse groups. 
17.2 Ongoing links with local community organisations should be developed to help 
make services in prisons and the community more accessible. Areas that could 
be	addressed	to	help	BME	patients	include:
•	 active	BME	staff	recruitment	(Race	Relations	(Amendment)	Act	2000);
•	 active	BME	prisoner	recruitment	for	Prisoner	Advisory	Drug	Services;
•	 staff	training	programmes;
•	 the	formulation	and	display	of	an	anti-discriminatory	policy	in	alliance	with	
prison	race	relation	teams	(HM	Prison	Service	1997);
•	 compilation	of	a	directory	of	BME	community	services,including	all	faith	
groups;
•	 links	with	interpreter	services;
•	 culturally	relevant	health	promotion	subject	matter	and	materials;
•	 particular	regard	to	confidentiality	issues;
•	 establishment	of	specialist	stimulant	teams.
17.3	 Further	guidance	on	the	successful	engagement	of	BME	drug	users	will	be	
issued shortly.
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18 Commissioning
18.1	 It	is	recognised	that	some	of	the	changes	described	in	this	document	will	have	
substantial funding implications.
18.2	 The	following	is	a	summary	of	the	clinical	developments	that	will	need	to	be	
planned through a joint commissioning framework:
•	 provision	of	prescribing	for	opiate	withdrawal	by	a	doctor	in	reception	of	
a local prison;
•	 introduction	of	five-day	stabilisation	via	methadone	or	buprenorphine;
•	 replacement	of	dihydrocodeine	as	a	primary	agent	for	detoxification;
•	 extension	of	opiate	detoxification	to	a	minimum	of	14	days;
•	 clinical	monitoring	of	stimulant	users	in	the	first	three	days	of	custody;
•	 introduction	of	short-term	(ie	13	weeks’)	opioid	maintenance;
•	 provision	of	adequate	training	and	support	for	all	clinicians	working	with	
substance misusers in prisons.
18.3	 It	may	be	anticipated	that	the	uptake	of	clinical	management	will	increase	in	
response	to	an	enhanced	service	provision.	NB:	Some	prisons	already	provide	
one or more of the above enhanced services.
18.4	 The	Department	of	Health	and	the	Home	Office	will	be	jointly	funding	the	
developments	described	in	this	document.	Further	guidance	on	commissioning	
the requisite elements of this integrated drug treatment system will be 
issued shortly.
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19 Confidentiality and joint working
19.1	 Joint	working	between	healthcare	and	CARAT	teams	will	be	vital	to	reduce	
multiple assessments and duplication of work. It may be the particular wish of 
a	patient	that	elements	of	their	medical	record	remain	a	confidential	matter	
between	themselves	and	the	healthcare	department	(blood-borne	virus	status	or	
details	of	sexual	health	are	possible	examples	of	sensitive	information).	Equally,	
a	CARAT	client	may	wish	details	of	their	personal	history	or	past	offending	to	
be	kept	as	a	confidence	between	the	CARAT	team	and	themselves.	For	these	
reasons,	it	is	important	that	separate	medical	records	and	CARAT	files	are	kept.	
However,	all	information	necessary	to	provide	the	patient	with	care	should	be	
shared between these services to provide the patient with continuity of care. 
Similarly,	all	information	necessary	to	safeguard	the	welfare	of	an	at-risk	patient	
who is to be released on licence should be shared with a probation team.
19.2	 For	further	information,	see	Appendix	C	of	this	document.
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20 Conclusion
20.1 This provides a vision of a schematic outline for approaches to the clinical 
management	of	substance	misuse.	None	of	these	treatments	are	stand	alone,	
but need to be delivered in a way that sees each stage as linked to the next, 
with the aim of promoting clear and coherent planned change that is self-driven 
and supported by the wider prison environment.
20.2 This document shall be reviewed within a year, in the light of any new research 
within the prison system, the improved training of prison doctors and the 
results	of	the	National	Institute	for	Health	and	Clinical	Excellence	guidance	
and technology appraisals of buprenorphine, methadone and naltrexone.
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Appendix A: Methadone and  
buprenorphine drug interactions
Methadone
Drugs	that	may	interact	with	methadone	to	reduce	its	effects:
Drug Function Potential interaction Note
Abacavir Antiretroviral Effects	reduced
Amprenavir Antiretroviral Effects	reduced
Barbiturates Sedatives
Anticonvulsants
1.	Effects	reduced
2.	Enhanced	central	
nervous system 
depression
Phenobarbital	can	lower	
methadone blood plasma 
levels.	Seek	advice
Buprenorphine Opioid analgesic Displacement	of	
methadone
Can	precipitate	
significant	withdrawal	
effects
Carbamazepine Anticonvulsant Effects	reduced
Efavirenz Antiretroviral Effects	reduced
Naltrexone Opioid antagonist Methadone	displaced Clinically	significant	
withdrawal effects
Nelfinavir Antiretroviral Effects	reduced
Nevirapine Antiretroviral Effects	reduced May	precipitate	opioid	
withdrawal
Phenytoin Anticonvulsant Accelerated methadone 
metabolism
Clinically	significant	
reduction in methadone 
plasma levels
Rifampicin Treatment of pulmonary 
tuberculosis
Accelerated methadone 
metabolism
Clinically	significant	–	can	
cause severe withdrawal
Spironolactone Diuretic Effects	reduced
Drugs	that	may	interact	with	methadone	to	increase	its	effects:
Drug Function Potential interaction Note
Cimetidine H2	antagonist	for	
gastrointestinal 
conditions
Raised methadone levels
Clarithromycin* Antibiotic Effects	increased
Erythromycin* Antibiotic Effects	increased
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Drug Function Potential interaction Note
Fluvoxamine* Selective	serotonin	
reuptake	inhibitor	(SSRI)	
antidepressant
Effects	increased Other	SSRIs	may	have	a	
similar action
Ketoconazole Antifungal treatment Effects	increased
Moclobemide Monoamine	oxidase	
inhibitor	(MAOI)	
antidepressant
1.	Effects	increased
2.	Hypotensive	and	
hypertensive reactions 
reported
Risk may apply to all 
MAOIs
Urinary	alkalinisers Treatment of renal 
conditions
Methadone	retained
Verapamil Cardiac	regulator Effects	increased
Other interactions between methadone and prescribed drugs:
Drug Function Potential interaction Note
Antihistamines	(non-
sedating)*	–	terfenadine,	
mizolastine
See*
Antipsychotics*	
(including	
chlorpromazine, 
haloperidol, droperidol)
Treatment of psychosis Enhanced	sedative	and	
hypotensive
Increased risk of toxicity 
with myelosuppressive 
drugs
Benzodiazepines Sedatives/hypnotics Enhanced	CNS	
depression
Domperidone* Antiemetic 1.	Methadone	blocks	
gastrointestinal activity
2.	Methadone	effect	
could be accelerated but 
not increased
Interferon	(alpha)	and	
ribavirin
Anti	hepatitis	C	
treatment
Side	effects	resemble	
opioid withdrawal
Methadone	dose	increase	
not necessarily indicated
Mexiletine Cardiac	regulator Delayed	absorption	of	
mexiletine 
Nifedipine Cardiac	regulator Increase in nifedipine
Opioids Analgesia Addictive effects Concomitant	prescribing	
may cause over-sedation
Stavudine Antiretroviral Decrease	in	stavudine	
blood plasma level
Methadone	levels	
unaffected
Tricyclics	(amitryptiline,	
desipramine, imipramine, 
notriptyline)
Antidepressants Increased triclyclic toxicity
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Drug Function Potential interaction Note
Zidovudine Antiretroviral Zidovudine	blood	plasma	
level increased
*	In	rare	cases,	these	drugs	may	interact	with	methadone	to	prolong	the	cardiac	QT	interval	(Leavitt	
and	Krantz	2003).	See	also	section	9.4	(lofexidine	detoxification).
Buprenorphine
Drugs	that	may	interact	with	Buprenorphine	to	reduce	its	effects:
Drug Function Potential interaction Note
Carbamazepine Anticonvulsant Effects	reduced
Naltrexone Opioid antagonist Buprenorphine displaced Clinically	significant	
withdrawal effects
Phenytoin Anticonvulsant Accelerated 
buprenorphine 
metabolism
Clinically	significant	
decrease in 
buprenorphine
Rifampicin Treatment of pulmonary 
tuberculosis
Accelerated 
buprenorphine 
metabolism
Clinically	significant	–	can	
cause severe withdrawal
Drugs	that	may	interact	with	buprenorphine	to	increase	its	effects:
Drug Function Potential interaction Note
Cimetidine H2	antagonist	for	
gastrointestinal 
conditions
Raised buprenorphine 
levels
Clarithromycin Antibiotic Effects	increased
Erythromycin Antibiotic Effects	increased
Fluvoxamine SSRI	antidepressant Effects	increased Other	SSRIs	may	have	a	
similar effect
Ketoconazole Antifungal treatment Effects	increased Clinically	significant	
Moclobemide MAOI	antidepressant Effects	increased
Hypotensive	and	
hypertensive reactions 
likely
Risk may apply to all 
MAOIs
Retonavir Antiretroviral Effects	increased Other protease inhibitors 
may react similarly
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Other interactions between buprenorphine and a prescribed drug:
Drug Function Potential interaction Note
Antipsychotics Treatment of psychosis Enhanced	sedative	and	
hypotensive
Increased risk of toxicity 
with myelosuppressive 
drugs
Barbiturates Sedatives
Anticonvulsants
Enhanced	CNS	
depression
Benzodiazepines Sedatives/hypnotics Enhanced	CNS	
depression
Domperidone* Antiemetic Buprenorphine blocks 
gastrointestinal activity
Buprenorphine effect 
could be accelerated but 
not increased
Interferon	(alpha)	and	
ribavirin
Anti	hepatitis	C	
treatment
Side	effects	resemble	
opioid withdrawal
Buprenorphine dose 
increase not necessarily 
indicated
Mexiletine Cardiac	regulator Delayed	absorption	of	
mexiletine 
Opioids Analgesia Addictive effects Concomitant	prescribing	
may cause over-sedation 
or precipitate severe 
withdrawals
Based on data from the British National Formulary	(British	Medical	Association	and	Royal	
Pharmaceutical	Society	of	Great	Britain	2005),	Leavitt	(2004)	and	Department	of	Health	(1999).
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Appendix B: DANOS competences for 
healthcare team members
There	are	more	than	100	Drug	and	Alcohol	National	Occupational	Standards	(DANOS)	units,	many	
of which are relevant to clinical substance misuse management in prisons.
The	following	is	an	outline	of	the	most	significant	milestones	of	clinical	management	of	substance	
dependence,	matched	to	corresponding	DANOS	units.
Area of 
intervention
Section DANOS unit
Initial healthcare 
screen
3.1 AA1: Recognise indications of substance misuse and refer 
individuals to specialists
AF1:	Carry	out	screening	and	referral	assessment
Clinical	drug	test 3.5 AE1:	Test	for	substance	misuse
Initial	(triage)	
substance misuse 
assessment
3.4 and 4.1 AF2:	Carry	out	triage	assessment	
Interim care plan for 
up	to	the	first	five	
days of custody
4.1 AG1:	Plan	and	agree	service	responses	which	meet	individuals’	
identified	needs	and	circumstances
Patient	begins	
treatment	(on	the	
first	night	where	
clinically indicated)
3.4 AH6:	Prepare	and	undertake	agreed	clinical	activities	with	
individuals in acute care settings
Medication	
administered 
to patient
5.4 AH2:	Prepare	and	administer	drugs	as	directed	or	prescribed	
by the clinician 
AH9:	Supervise	methadone	(and	other	controlled	drug	
consumption)
Patient	may	be	at	
risk of suicide or a 
medical emergency 
as a consequence of 
withdrawal
5.4 
and
9
AB5: Assess and act upon immediate risk of danger to individuals 
who have used substances 
AH7:	Support	individuals	through	detoxification	programmes
Patient	may	be	at	
risk of overdose 
throughout custody
6 AB5: Assess and act upon immediate risk of danger to individuals 
who have used substances
Formal	care	plan	at	
five	days
5.1 AF3:	Carry	out	comprehensive	substance	misuse	assessment
AG2:	Contribute	to	the	development,	provision	and	review	of	
care programmes
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Area of 
intervention
Section DANOS unit
Patient	may	be	
unaware of risks 
associated with 
substance misuse 
15 AD1:	Raise	awareness	about	substances,	their	use	and	effects
AB2:	Support	individuals	who	are	substance	users
Patient	transfers	to	
another prison or is 
released
11 AG3:	Assist	in	the	transfer	of	individuals	between	agencies	and	
services
Patient	is	released 11 AH5:	Undertake	agreed	clinical	activities	with	individuals	(such	
as initiation of a naltrexone programme) whose health is stable 
in non-acute care settings 
AH8:	Dispense	medicines	and	products
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Appendix C: Consent and 
confidentiality
For	people	to	have	the	capacity	to	give	informed	consent	to	a	clinical	intervention,	
they must be able to comprehend and retain information that is material to their 
decision. They must be advised of the consequences of both having and not having 
the intervention in question, and have the time and capacity to use and weigh this 
information in the decision-making process.
Patients	must	be	made	aware	that	the	information	they	give	may	be	recorded,	may	
be shared with their consent, in order to provide them with care, and may be used 
to support clinical audit and other work to monitor the quality of care provided.
In order to inform patients properly, staff must:
a.		 check	where	practicable	that	information	leaflets	on	patient	confidentiality	
and information disclosure have been read and understood;
b.  make clear to patients when information is recorded or health records 
are accessed;
c.  make clear to patients when they are or will be disclosing information 
with others;
d.  check that patients are aware of the choices available to them in respect 
of how their information may be disclosed and used;
e. check that patients have no concerns or queries about how their 
information is disclosed and used;
f. answer any queries personally or direct the patient to others who can 
answer their questions or other sources of information;
g. respect the rights of patients and facilitate them in exercising their right 
to have access to their health records.
There	is	a	range	of	statutory	provisions	that	influence	the	way	in	which	patient	
information	is	used	or	disclosed.	Details	of	these	can	be	found	on	the	Department	
of	Health	website	at	www.dh.gov.uk/PublicationsAndStatistics/Publications/
PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_
ID=4069253&chk=jftKB%2B
The	key	principle	of	the	common	law	of	confidentiality	is	that	information	confided	
should	not	be	used	or	disclosed	further,	except	as	originally	understood	by	the	confider	
or with their subsequent permission
While	judgments	have	established	that	confidentiality	can	be	breached	‘in	the	
public	interest’,	these	have	centred	on	case-by-case	consideration	of	exceptional	
circumstances.	Confidentiality	can	also	be	overridden	or	set	aside	by	legislation.
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Under	common	law,	staff	are	permitted	to	disclose	personal	information	(to,	for	
instance,	a	probation	officer)	in	order	to	support	detection,	investigation	and	
punishment of serious crime and/or to prevent abuse or serious harm to others where 
they judge, on a case-by-case basis, that the public good that would be achieved by 
the	disclosure	outweighs	both	the	obligation	of	confidentiality	to	the	individual	patient	
concerned	and	the	broader	public	interest	in	the	provision	of	a	confidential	service.
The	Data	Protection	Act	1998	imposes	constraints	on	the	processing	of	personal	
information	in	relation	to	living	individuals.	It	identifies	eight	data	protection	principles	
which set out standards for information handling.
In	the	context	of	confidentiality,	the	most	significant	principles	are:
•	 the	first,	which	requires	processing	to	be	fair	and	lawful	and	imposes	
other restrictions;
•	 the	second,	which	requires	personal	data	to	be	processed	for	one	or	more	
specified	and	lawful	purposes;
•	 the	seventh,	which	requires	personal	data	to	be	protected	against	
unauthorised or unlawful processing and against accidental loss,  
destruction or damage.
Within	the	Human	Rights	Act	1998	there	is	a	requirement	that	actions	that	interfere	
with	the	right	to	respect	for	private	and	family	life	(eg	disclosing	confidential	
information)	must	also	be	justified	as	being	necessary	to	support	legitimate	aims	
and be proportionate to the need.
Current	understanding	is	that	compliance	with	the	Data	Protection	Act	1998	and	the	
common	law	of	confidentiality	should	satisfy	Human	Rights	Act	requirements.
From	Department	of	Health	(2003).
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Appendix D: Management of opiate 
overdose
Opiate overdose is characterised by:
•	 constricted	(pinned)	pupils	(although	dilation	can	occur);
•	 respiratory	depression/cyanosis;
•	 pulmonary	oedema	(frothing	from	the	lung);
•	 sweating;
•	 hypotension	and	bradycardia;
•	 unconsciousness.
Opiate overdose should be treated by resuscitation with oxygen.
Emergency	administration	of	0.8	to	2mg	naloxone	should	be	given	I/V	or	I/M	
and repeated as necessary on account of its short half-life relative to heroin 
and methadone. 
In an emergency, naloxone may be administered by parenteral injection by any 
competent member of the healthcare team (HMSO 2005).
An emergency ambulance transfer to an outside hospital must be arranged. The patient 
must be observed closely for 24 hours following return from hospital, as a secondary 
episode of respiratory depression can follow the discontinuation of naloxone treatment.
In the event of a suspected buprenorphine overdose, substantially more naloxone may 
be required.
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